Gioacchino Tedeschi

Gioacchino Tedeschi

Full Professor of Neurology, Chief of the First Division of Neurology

Prof. Gioacchino Tedeschi is Full Professor of Neurology and Chief of the First  Division of  Neurology,  University  of  Campania “Luigi Vanvitelli” in  Naples (Italy) (respectively from 2000 and 2010).  He was Research  Assistant and Visiting  Research  Fellow, respectively from 1982 to 1983 and from 1990 to 1992, at the Department  of Pharmacology  and  Therapeutics, University of Cardiff, Cardiff (UK). He was Assistant  Professor of Neurology, from 1984 to 1992, and Associate  Professor  of  Neurology, from 1995 to 2000, at the Second University of Naples (Italy). From 1993 to 1996, he was Visiting  Scientist at the Neuroimaging  Branch, National  Institutes  of Health, Bethesda, MD, USA. Prof. Tedeschi, whose main areas of research are neuroimaging/clinical trials applied to dementia, headache/migraine, multiple sclerosis, movement disorders and ALS, has been President of the Italian Society of Neurology (SIN) from 2019 to 2021. He is a member of the Italian ALS Genetic (ITALSGEN) Consortium (2010- today) and of the Neuroimaging  Society  in Amyotrophic  Lateral  Sclerosis (NiSALS) (2014-today).

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more